All In Biotech

Drug Trial Radar · NCT06482112

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

A Phase 2a Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Different Dosing Regimens of Efinopegdutide (MK-6024) in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 124 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Jul 29, 2024

Primary completion

Jun 27, 2025

Study completion Jun 27, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and tolerability of the different regimens of efinopegdutide.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Non-alcoholic Fatty Liver Disease
  • Nonalcoholic Fatty Liver Disease
  • Liver Disease

Interventions

  • EfinopegdutideDrug

    SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Relative Reduction From Baseline in Liver Fat Content at Week 28Time frame: Baseline and Week 28
  2. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to Week 32
  3. Percentage of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to Week 28

Locations

39 sites in 2 countries. Site status is shown where the registry gives one.

  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0

    Chandler, Arizona

  • The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0224)

    Peoria, Arizona

  • Arizona Liver Health ( Site 0211)

    Tucson, Arizona

  • Del Sol Research Management, LLC ( Site 0209)

    Tucson, Arizona

  • Om Research LLC ( Site 0207)

    Camarillo, California

  • Gastroenterology and Liver Institute ( Site 0263)

    Escondido, California

  • Velocity Clinical Research, Gardena ( Site 0235)

    Gardena, California

  • Velocity Clinical Research, Huntington Park ( Site 0210)

    Huntington Park, California

  • California Liver Research Institute ( Site 0216)

    Pasadena, California

  • Acclaim Clinical Research ( Site 0241)

    San Diego, California

  • Velocity Clinical Research, Santa Ana ( Site 0250)

    Santa Ana, California

  • Velocity Clinical Research, Panorama City ( Site 0228)

    Van Nuys, California

  • Excel Medical Clinical Trials ( Site 0268)

    Boca Raton, Florida

  • AGA Clinical Trials ( Site 0274)

    Hialeah, Florida

  • Neoclinical Research ( Site 0275)

    Hialeah, Florida

  • Homestead Associates in Research, Inc. ( Site 0243)

    Homestead, Florida

  • Floridian Clinical Research, LLC ( Site 0208)

    Miami Lakes, Florida

  • Southeast Clinical Research Center ( Site 0223)

    Dalton, Georgia

  • Velocity Clinical Research Rockville ( Site 0245)

    Rockville, Maryland

  • The Machuca Foundation ( Site 0218)

    Las Vegas, Nevada

  • Excel Clinical Research, LLC ( Site 0200)

    Las Vegas, Nevada

  • Basil Clinical ( Site 0246)

    Inwood, New York

  • Lucas Research, Inc ( Site 0204)

    Morehead City, North Carolina

  • Texas Clinical Research Institute ( Site 0230)

    Arlington, Texas

  • Pinnacle Clinical Research ( Site 0203)

    Austin, Texas

  • Velocity Clinical Research, Austin ( Site 0201)

    Austin, Texas

  • Pinnacle Clinical Research-Corpus Christi ( Site 0267)

    Corpus Christi, Texas

  • Zenos Clinical Research ( Site 0240)

    Dallas, Texas

  • South Texas Research Institute ( Site 0226)

    Edinburg, Texas

  • Houston Research Institute ( Site 0221)

    Houston, Texas

  • American Research Corporation ( Site 0234)

    San Antonio, Texas

  • Clinical Trials of Texas, LLC-Clinical Research ( Site 0252)

    San Antonio, Texas

  • Pinnacle Clinical Research-Clinical Research Coordination ( Site 0229)

    San Antonio, Texas

  • Impact Research Institute ( Site 0227)

    Waco, Texas

  • Olympus Family Medicine/CCT Research ( Site 0266)

    Holladay, Utah

  • South Ogden Family Medicine/ CCT Research ( Site 0255)

    South Ogden, Utah

  • San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0104)

    Caguas, Puerto Rico

  • Klinical Investigations Group-Clinical Research ( Site 0100)

    San Juan, Puerto Rico

  • Pan American Center for Oncology Trials - Ciudadela ( Site 0101)

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.